CryoTherapeutics is developing its CTS system, designed to provide intracoronary cryotherapy treatment for patients with high-risk plaque lesions (also called vulnerable plaque) , who are (at risk of) suffering a heart attack, as confirmed by diagnostic methods. The first in human clinical trial is currently ongoing, as part of a robust clinical program to prove the safety and efficacy of the CTS system for approval and launch of the technology on the market. . Current activities also include further product development to support the programs and optimize clinical applicability. Based on this we aim to become a major participant in the market for minimally invasive treatment of coronary artery disease.



CryoTherapeutics closes new €12.3 million financing round.

Find out more